A.M. Pappas & Associates

A.M. Pappas & Associates is a venture capital firm specializing in life sciences investments, focusing on biotechnology and pharmaceutical companies. The firm is dedicated to the development of life science companies, products, technologies, and other significant entrepreneurial opportunities. It manages Pappas Ventures, a family of life science venture funds, and is developing university-focused translational medicine initiatives. A.M. Pappas & Associates has $350 million in capital under management.

The firm's investment strategy involves early to mid-stage investments, ranging from $100,000 seed deals to $6 million later-stage mezzanine transactions. It has invested in more than 100 companies across the United States, Canada, and Asia, focusing on a wide range of human diseases. The products its companies have brought to market have been used throughout the world to treat tens of thousands of patients and account for billions of dollars in revenue.

A.M. Pappas & Associates also provides a broad range of licensing, technology assessment, technology transfer, and other advisory services to the life science industry. Its portfolio includes companies such as Plexxikon (acquired by Daiichi Sankyo), Ultragenyx Pharmaceutical (IPO), Lumena Pharmaceuticals (acquired by Shire), LEAD Therapeutics (acquired by BioMarin Pharmaceutical), and Balance Therapeutics. The firm operates offices in Research Triangle Park, North Carolina, and San Francisco, California, and has a global presence in the U.S., Europe, and Asia.